KYORIN Pharmaceutical Co., Ltd.

PickUp

These websites are only available in Japanese.

News Releases

October 16, 2025: Announcement of Presentation in Academic Conference Regarding Result of Specified Clinical Trial using Digital Therapeutics for Tinnitus
October 1, 2025: KYORIN and Hinge Bio Enter into a Collaboration and License Agreement of HB2198 in Japan for SLE and other diseases
September 16, 2025: Topline Results from Phase 3 Clinical Study of KRP-R120 for Interstitial Lung Disease
July 31, 2025: Summary of Consolidated Financial Results (For the First Quarter ended June 30, 2025) [Under Japanese GAAP]
July 31, 2025: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2026

About Kyorin

KYORIN Holdings, Inc. has merged its wholly owned subsidiary KYORIN Pharmaceutical. Co., Ltd and has changed its trade name to “KYORIN Pharmaceutical. Co., Ltd.” on April 2023.

More detail

Investor Relations

This section provides information on the long-term vision, medium-term business plan, financial and performance results, IR library and stock.

More detail

Sustainability

Following our corperate philosophy, Kyorin Group is working to contribute to society’s continuous development and our sustainable growth by fulfilling our social responsibility through we business activities with new drug as our core business.

More detail

R&D

A large number of unmet medical needs are still present in the world. This section provides information on our initiatives for drug discovery, and development pipeline.

More detail

PickUp

News Releases

Contens

About Kyorin

Investor Relations

Sustainability

R&D

Kyorin Group